AI-designed drug candidate shows promise for gastric acid inhibition

Researchers at Nagoya University in Japan created and improved artificial intelligence (AI) designs to synthesize a candidate compound for a new gastric acid inhibitor with a better binding affinity than existing drugs.

Rivus posts a win for its experimental obesity drug in heart failure patients

Rivus Pharmaceuticals’ experimental cardiometabolic drug, HU6, nailed a mid-stage trial in obese patients with heart failure, finding that patients notched a statistically significant reduction in

August 14, 2024

Study uncovers the role of mGluR1 in pruning early neural connections

Not everything in the brain is meant to last. As our brains assemble, trillions of neural connections have to be built or torn down at

July 1, 2024

The abrupt end of USAID-funded clinical trials is profoundly unethical

The path from the atrocities of Nuremberg and Tuskegee to today’s robust ethics of medical research has not been easy. In response to these horrific

February 16, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.